P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL.

MLA

Tural, C., et al. “P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON A-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL.” Journal of Hepatology, vol. 60, Apr. 2014, p. S469. EBSCOhost, https://doi.org/10.1016/S0168-8278(14)61317-9.

APA

Tural, C., Rockstroh, J. K., Nelson, M., Bhagani, S., Ingiliz, P., Soriano, V., Núñez, M., Valantin, M.-A., Valdez Madruga, J., Rauch, A., Furtado, J., Battegay, M., Stern, J. O., Quinson, A.-M., Böcher, W., Vinisko, R., Manero, M., & Dieterich, D. (2014). P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL. Journal of Hepatology, 60, S469. https://doi.org/10.1016/S0168-8278(14)61317-9

Chicago

Tural, C., J.K. Rockstroh, M. Nelson, S. Bhagani, P. Ingiliz, V. Soriano, M. Núñez, et al. 2014. “P1157 IMPACT OF BASELINE VARIABLES ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON A-2a AND RIBAVIRIN IN PATIENTS WITH HIV/HCV GENOTYPE-1 COINFECTION IN A PHASE III TRIAL.” Journal of Hepatology 60 (April): S469. doi:10.1016/S0168-8278(14)61317-9.